Actavis, Inc. (ACT) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2013

Actavis, Inc.

CIK: 884629

Exhibit 99.1





CONTACTS:   Investors:
  Lisa DeFrancesco
  (862) 261-7152
  Charlie Mayr
  (862) 261-8030
  David Belian
  (862) 261-8141

Actavis Net Revenue Increases 57% to $2.01 Billion in Third Quarter 2013; Non-GAAP EPS Increases 55% to $2.09

- GAAP Earnings Per Share of $0.49 -

- 61% Increase in Adjusted EBITDA to $489 million -

- Company Updates 2013 Forecast, Provides Preliminary 2014 Outlook -

DUBLIN – October 29, 2013 –

Actavis plc (NYSE: ACT) today reported net revenue increased 57 percent to $2.01 billion for Actavis, Inc.’s third quarter 2013, compared to $1.29 billion in the third quarter 2012. On a non-GAAP basis, diluted earnings per share for the third quarter 2013 were $2.09, compared to $1.35 per diluted share in the third quarter 2012, an increase of 55 percent. GAAP earnings per diluted share for the third quarter 2013 were $0.49, compared to GAAP earnings per diluted share of $0.60 in the prior year period. These reported results exclude any results from Warner Chilcott plc, which Actavis plc acquired on October 1, 2013.

For the third quarter 2013, adjusted EBITDA increased 61 percent to $489.2 million, compared to $304.6 million for the third quarter 2012. Cash flow from operations for the third quarter of 2013 was $270.8 million and cash and marketable securities were $373.5 million as of September 30, 2013.

“Double-digit revenue and earnings growth marked another exceptional quarter for Actavis, Inc., as we continue to accelerate our transformation into a global specialty pharmaceutical leader,” said Paul Bisaro, Chairman and CEO of Actavis plc.



The following information was filed by Actavis, Inc. on Tuesday, October 29, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Actavis, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actavis, Inc..


Assess how Actavis, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actavis, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 884629
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-13-419835
Submitted to the SEC: Thu Oct 31 2013 9:17:27 AM EST
Accepted by the SEC: Thu Oct 31 2013
Period: Monday, September 30, 2013
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: